A chest radiograph of a patient with idiopathic pulmonary fibrosis (IPF). Credit: IPFeditor.

Galapagos has released the PINTA Phase ll trial design that aims to investigate GLPG1205 to treat patients with idiopathic pulmonary fibrosis (IPF).

Up to 60 IPF patients are expected to be enrolled in the randomised, double-blind, placebo-controlled trial.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the trial, a 100mg once-daily oral dose of GLPG1205 or placebo will be provided to the subjects for a period of 26 weeks.

Patients can choose to remain on their local standard of care as background therapy.

PINTA’s primary objective is to evaluate the change from baseline in forced vital capacity (FVC) over 26 weeks compared to placebo.

Its secondary measures comprise safety, tolerability, pharmacokinetics and pharmacodynamics, time to major events, changes in functional exercise capacity, and quality of life.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“GLPG1205 has shown signs of good activity in relevant animal models, and GPR84 has already been validated as a mechanism in combination with nintedanib in IPF.”

The trial intends to measure IPF diagnosis by central reading.

In addition, it plans to enrol patients across ten countries in Europe, North Africa, and the Middle East, and expects to dose the first patient by the second half of this year.

Galapagos chief scientific officer Dr Piet Wigerinck said: “GLPG1205 has shown signs of good activity in relevant animal models, and GPR84 has already been validated as a mechanism in combination with nintedanib in IPF.

“We have a well-designed trial with PINTA for ‘1205 that we anticipate will give us new insights into the potential value of GPR84 inhibition as a mechanism to treat this highly fatal disease.”

IPF is a chronic, persistently progressive fibrotic disorder of the lungs that usually affects adults over the age of 40.

Around 200,000 people are currently estimated to be diagnosed with IPF in the US and Europe.